Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01400516 · ClinicalTrials.gov registry record · Phase 4
Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT01400516 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 26 participants.
The verdict
NCT01400516, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
Summary: The investigators propose a randomized controlled open label study of teriparatide in men or women with rheumatoid arthritis and joint erosions. Specifically, the investigators will examine whether teriparatide in combination with a biologic can retard the development of joint erosions. The study will be conducted at Brigham and Women's Hospital Arthritis Center, several Brigham and Women's Hospital Arthritis Center satellite practices, the University of Massachusetts Medical Center, and Massachusetts General Hospital. Hypothesis: The investigators hypothesize that the combination of teriparatide with biologic will be much more effective at retarding erosion progression then a biologic alone.
Interventions
- DRUG Teriparatide
- DRUG Vitamin D
- DRUG calcium citrate
- DRUG TNF antagonist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-08 |
| Est. Completion | 2016-07-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01400516
The ClinicalTrials.gov registry entry for NCT01400516 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Teriparatide is the first listed.
NCT01400516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01400516 about?
NCT01400516 is a clinical study titled "Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial". Summary: The investigators propose a randomized controlled open label study of teriparatide in men or women with rheumatoid arthritis and joint erosions. Specifically, the investigators will examine whether teriparatide in combination with a biologic can retard the development of joint erosions. Th...
What is the current status of trial NCT01400516?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2011-08. Estimated completion is 2016-07-28.
What interventions are being tested in trial NCT01400516?
The interventions under investigation include: Teriparatide (DRUG), Vitamin D (DRUG), calcium citrate (DRUG), TNF antagonist (DRUG).
Who is sponsoring clinical trial NCT01400516?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.